Abstract
Drug use and the associated overdose deaths have been a serious public health threat in the United States and the world. While traditional drugs of abuse such as cocaine remain popular, recreational use of newer synthetic drugs has continued to increase, but the prevalence of use is likely underestimated. In this review, epidemiology, chemistry, pharmacophysiology, clinical effects, laboratory detection, and clinical treatment are discussed for newly emerging drugs of abuse in the following classes: (1) opioids (e.g., fentanyl, fentanyl analogues, and mitragynine), (2) cannabinoids [THC and its analogues, alkylindole (e.g., JWH-018, JWH-073), cyclohexylphenol (e.g., CP-47,497), and indazole carboxamide (e.g., FUB-AMB, ADB-FUBINACA)], (3) stimulants and hallucinogens [β-keto amphetamines (e.g., methcathinone, methylone), pyrrolidinophenones (e.g., α-PVP, MDPV), and dimethoxyphenethylamine (“2C” and “NBOMe”)], (4) dissociative agents (e.g., 3-MeO-PCP, methoxetamine, 2-oxo-PCE), and (5) sedative-hypnotics (e.g., gabapentin, baclofen, clonazolam, etizolam). It is critically important to coordinate hospital, medical examiner, and law enforcement personnel with laboratory services to respond to these emerging threats.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aizpurua-Olaizola O, Soydaner U, Ozturk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (2016) Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J Nat Prod 79:324–331. https://doi.org/10.1021/acs.jnatprod.5b00949
Andre CM, Hausman JF, Guerriero G (2016) Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci 7:19. https://doi.org/10.3389/fpls.2016.00019
Arbo MD, Bastos ML, Carmo HF (2012) Piperazine compounds as drugs of abuse. Drug Alcohol Depend 122:174–185. https://doi.org/10.1016/j.drugalcdep.2011.10.007
Armenian P, Vo KT, Barr-Walker J, Lynch KL (2018) Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology 134:121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016
Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B (2013) Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 37:284–290. https://doi.org/10.1093/jat/bkt024
Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837. https://doi.org/10.1002/jms.1558
Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92:2457–2473. https://doi.org/10.1007/s00204-018-2244-6
Behzadi M, Joukar S, Beik A (2018) Opioids and cardiac arrhythmia: a literature review. Med Princ Pract 27:401–414. https://doi.org/10.1159/000492616
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (2010) A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 49:661–669. https://doi.org/10.2165/11536200-000000000-00000
Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (2018) Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol. Neuropsychopharmacology 43:142–154. https://doi.org/10.1038/npp.2017.209
Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R (2017) Labeling accuracy of cannabidiol extracts sold online. JAMA 318:1708–1709. https://doi.org/10.1001/jama.2017.11909
Boom M, Niesters M, Sarton E, Aarts L, Smith TW, Dahan A (2012) Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des 18:5994–6004
Boyer EW (2012) Management of opioid analgesic overdose. N Engl J Med 367:146–155. https://doi.org/10.1056/NEJMra1202561
Brand EJ, Zhao Z (2017) Cannabis in chinese medicine: are some traditional indications referenced in ancient literature related to cannabinoids? Front Pharmacol 8:108. https://doi.org/10.3389/fphar.2017.00108
Brents LK, Prather PL (2014) The K2/spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 46:72–85. https://doi.org/10.3109/03602532.2013.839700
Brittain RT, Kellett DN, Neat ML, Stables R (1973) Proceedings: anti-nociceptive effects in N-substituted cyclohexylmethylbenzamides. Br J Pharmacol 49:158P–159P
Broseus J, Gentile N, Esseiva P (2016) The cutting of cocaine and heroin: a critical review. Forensic Sci Int 262:73–83. https://doi.org/10.1016/j.forsciint.2016.02.033
Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH (2018) Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014–2017. Clin Toxicol (Phila) 57(4):282–286. https://doi.org/10.1080/15563650.2018.1510502
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41. https://doi.org/10.1016/j.drugalcdep.2014.08.005
Cayman Chemical Standardized Naming of Substituted Fentanyls. https://www.caymanchem.com/Literature/standardized-naming-of-substituted-fentanyls. Accessed 4 Dec 2018
Chen P, Braithwaite RA, George C, Hylands PJ, Parkin MC, Smith NW, Kicman AT (2014) The poppy seed defense: a novel solution. Drug Test Anal 6:194–201. https://doi.org/10.1002/dta.1590
Childress SJ, Gluckman MI (1964) 1,4-Benzodiazepines. J Pharm Sci 53:577–590
Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, Corkery J, Trincas G, Deluca P, Davey Z, Blaszko U, Demetrovics Z, Moskalewicz J, Enea A, di Melchiorre G, Mervo B, di Furia L, Farre M, Flesland L, Pasinetti M, Pezzolesi C, Pisarska A, Shapiro H, Siemann H, Skutle A, Enea A, di Melchiorre G, Sferrazza E, Torrens M, van der Kreeft P, Zummo D, Scherbaum N (2012) Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum Psychopharmacol 27:145–149. https://doi.org/10.1002/hup.1242
Corazza O, Assi S, Schifano F (2013) From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 19:454–460. https://doi.org/10.1111/cns.12063
Daniulaityte R, Juhascik MP, Strayer KE, Sizemore IE, Harshbarger KE, Antonides HM, Carlson RR (2017) Overdose deaths related to fentanyl and its analogs – Ohio, January-February 2017. MMWR Morb Mortal Wkly Rep 66:904–908. https://doi.org/10.15585/mmwr.mm6634a3
Devereaux AL, Mercer SL, Cunningham CW (2018) DARK classics in chemical neuroscience: morphine. ACS Chem Neurosci 9:2395–2407. https://doi.org/10.1021/acschemneuro.8b00150
Dinis-Oliveira RJ (2017) Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev 49:84–91. https://doi.org/10.1080/03602532.2016.1278228
Dominguez-Clave E, Soler J, Elices M, Pascual JC, Alvarez E, de la Fuente RM, Friedlander P, Feilding A, Riba J (2016) Ayahuasca: pharmacology, neuroscience and therapeutic potential. Brain Res Bull 126:89–101. https://doi.org/10.1016/j.brainresbull.2016.03.002
Domino EF (2008) Dr. Paul: views through the piperidine ring. Anesth Analg 107:723–724; author reply 724. https://doi.org/10.1213/ane.0b013e31817c737d
Dove HW (1984) Phencyclidine: pharmacologic and clinical review. Psychiatr Med 2:189–209
Downes MA, Berling IL, Mostafa A, Grice J, Roberts MS, Isbister GK (2015) Acute behavioural disturbance associated with phenibut purchased via an internet supplier. Clin Toxicol (Phila) 53:636–638. https://doi.org/10.3109/15563650.2015.1059945
Drug Enforcement Administration (DEA) (2017) 2017 National drug threat assessment. In: U.S. Department of Justice (ed)
Drug Enforcement Administration (DEA) (2018a) 2018 National drug threat assessment. In: U.S. Department of Justice (ed)
Drug Enforcement Administration (DEA) (2018b) Emerging threat report, annual 2017. In: U.S. Department of Justice (ed)
Drug Enforcement Administration (DEA) (2018c) Emerging threat report, mid-year 2018. In: U.S. Department of Justice (ed)
ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry 79:613–619. https://doi.org/10.1016/j.biopsych.2016.01.004
European Monitoring Centre for Drugs and Drug Addiction (2009) Understanding the ‘Spice’ phenomenon. Publications Office of the European Union, Luxembourg
European Monitoring Centre for Drugs and Drug Addiction (2018) Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System. Publications Office of the European Union, Luxembourg
Florence CS, Zhou C, Luo F, Xu L (2016) The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care 54:901–906. https://doi.org/10.1097/MLR.0000000000000625
Ford TC, Hayley AC, Downey LA, Parrott AC (2017) Cannabis: an overview of its adverse acute and chronic effects and its implications. Curr Drug Abuse Rev 10:6–18. https://doi.org/10.2174/1874473710666170712113042
Gatch MB, Forster MJ (2018) Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. Neurotoxicology 70:72–79. https://doi.org/10.1016/j.neuro.2018.11.004
Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G (2016) Molecular pharmacology of delta-opioid receptors. Pharmacol Rev 68:631–700. https://doi.org/10.1124/pr.114.008979
Genzen JR, Mohlman JS, Lynch JL, Squires MW, Weiss RL (2017) Laboratory-developed tests: a legislative and regulatory review. Clin Chem 63:1575–1584. https://doi.org/10.1373/clinchem.2017.275164
Glicksberg L, Bryand K, Kerrigan S (2016) Identification and quantification of synthetic cathinones in blood and urine using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 1035:91–103. https://doi.org/10.1016/j.jchromb.2016.09.027
Goldberger BA, Darwin WD, Grant TM, Allen AC, Caplan YH, Cone EJ (1993) Measurement of heroin and its metabolites by isotope-dilution electron-impact mass spectrometry. Clin Chem 39:670–675
Goldstein RA, DesLauriers C, Burda AM (2009) Cocaine: history, social implications, and toxicity--a review. Dis Mon 55:6–38. https://doi.org/10.1016/j.disamonth.2008.10.002
Graddy R, Buresh ME, Rastegar DA (2018) New and emerging illicit psychoactive substances. Med Clin North Am 102:697–714. https://doi.org/10.1016/j.mcna.2018.02.010
Grinberga S, Zvejniece L, Liepinsh E, Dambrova M, Pugovics O (2008) Quantitative analysis of phenibut in rat brain tissue extracts by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 22:1321–1324. https://doi.org/10.1002/bmc.1059
Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360. https://doi.org/10.2165/00003088-200342040-00003
Guy GP Jr, Zhang K, Bohm MK, Losby J, Lewis B, Young R, Murphy LB, Dowell D (2017) Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep 66:697–704. https://doi.org/10.15585/mmwr.mm6626a4
Hassamal S, Miotto K, Dale W, Danovitch I (2018) Tramadol: understanding the risk of serotonin syndrome and seizures. Am J Med 131:1382.e1–1382.e6. https://doi.org/10.1016/j.amjmed.2018.04.025
Hedegaard H, Warner M, Minino AM (2017) Drug overdose deaths in the United States, 1999-2016. NCHS Data Brief 294:1–8
Helander A, Beck O, Backberg M (2015) Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) 53:446–453. https://doi.org/10.3109/15563650.2015.1033630
Hill SL, Dunn M, Cano C, Harnor SJ, Hardcastle IR, Grundlingh J, Dargan PI, Wood DM, Tucker S, Bartram T, Thomas SHL (2018) Human toxicity caused by indole and indazole carboxylate synthetic cannabinoid receptor agonists: from horizon scanning to notification. Clin Chem 64:346–354. https://doi.org/10.1373/clinchem.2017.275867
Horsfall JT, Sprague JE (2017) The pharmacology and toxicology of the ‘Holy Trinity’. Basic Clin Pharmacol Toxicol 120:115–119. https://doi.org/10.1111/bcpt.12655
Hou XL, Wu YL, Chen RX, Zhu Y, Lv Y, Xu XQ (2014) Evaluation of two modified quick, easy, cheap, effective, rugged and safe (QuEChERS) sample preparation methods for the analysis of baclofen and gabapentin in feeds by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 88:53–59. https://doi.org/10.1016/j.jpba.2013.08.026
Howlett AC, Champion TM, Wilken GH, Mechoulam R (1990) Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology 29:161–165
Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS (2018) Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 361:eaau1184. https://doi.org/10.1126/science.aau1184
Jansen KL, Prast CJ (1988) Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol 23:115–119
Jembrek MJ, Vlainic J (2015) GABA receptors: pharmacological potential and pitfalls. Curr Pharm Des 21:4943–4959
Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT (2018) A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther 7:13–21. https://doi.org/10.1007/s40122-018-0097-6
Kalix P (1992) Cathinone, a natural amphetamine. Pharmacol Toxicol 70:77–86
Karch SB (2015) Cathinone neurotoxicity (“The 3Ms”). Curr Neuropharmacol 13:21–25. https://doi.org/10.2174/1570159X13666141210225009
Katz KD, Leonetti AL, Bailey BC, Surmaitis RM, Eustice ER, Kacinko S, Wheatley SM (2016) Case series of synthetic cannabinoid intoxication from one toxicology center. West J Emerg Med 17:290–294. https://doi.org/10.5811/westjem.2016.2.29519
Ketha H, Webb M, Clayton L, Li S (2017) Gas chromatography mass spectrometry (GC-MS) for identification of designer stimulants including 2C amines, NBOMe compounds, and cathinones in urine. Curr Protoc Toxicol 74:4.43.1–4.43.10. https://doi.org/10.1002/cptx.33
King AM, Pugh JL, Menke NB, Krasowski MD, Lynch MJ, Pizon AF (2013) Nonfatal tramadol overdose may cause false-positive phencyclidine on Emit-II assay. Am J Emerg Med 31(444):e5–e9. https://doi.org/10.1016/j.ajem.2012.05.028
Knittel JL, Holler JM, Chmiel JD, Vorce SP, Magluilo J Jr, Levine B, Ramos G, Bosy TZ (2016) Analysis of parent synthetic cannabinoids in blood and urinary metabolites by liquid chromatography tandem mass spectrometry. J Anal Toxicol 40:173–186. https://doi.org/10.1093/jat/bkv137
Krasowski MD, Ekins S (2014) Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. J Cheminform 6:22. https://doi.org/10.1186/1758-2946-6-22
Krasowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S (2009) Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 9:5. https://doi.org/10.1186/1471-227X-9-5
Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER (2012) Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest 122:3387–3393. https://doi.org/10.1172/JCI60390
Kruegel AC, Grundmann O (2018) The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology 134:108–120. https://doi.org/10.1016/j.neuropharm.2017.08.026
Kulig K (2017) Interpretation of workplace tests for cannabinoids. J Med Toxicol 13:106–110. https://doi.org/10.1007/s13181-016-0587-z
Lakhan SE, Caro M, Hadzimichalis N (2013) NMDA receptor activity in neuropsychiatric disorders. Front Psychiatry 4:52. https://doi.org/10.3389/fpsyt.2013.00052
Lapin I (2001) Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 7:471–481
Lappin JM, Darke S, Farrell M (2017) Stroke and methamphetamine use in young adults: a review. J Neurol Neurosurg Psychiatry 88:1079–1091. https://doi.org/10.1136/jnnp-2017-316071
Laskowski LK, Elbakoush F, Calvo J, Exantus-Bernard G, Fong J, Poklis JL, Poklis A, Nelson LS (2015) Evolution of the NBOMes: 25C- and 25B- sold as 25I-NBOMe. J Med Toxicol 11:237–241. https://doi.org/10.1007/s13181-014-0445-9
Law R, Schier J, Martin C, Chang A, Wolkin A, Centers for Disease C (2015) Notes from the field: increase in reported adverse health effects related to synthetic cannabinoid use – United States, January–May 2015. MMWR Morb Mortal Wkly Rep 64:618–619
Lee HZS, Ong MC, Lim JLW, Yap TWA (2017) Challenges in GC-MS analysis: case studies on phenibut and ethylphenidate. Forensic Sci Int 277:166–178. https://doi.org/10.1016/j.forsciint.2017.06.002
Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720–726
Ling GS, Spiegel K, Lockhart SH, Pasternak GW (1985) Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 232:149–155
Listos J, Merska A, Fidecka S (2011) Pharmacological activity of salvinorin A, the major component of Salvia divinorum. Pharmacol Rep 63:1305–1309
Litjens RP, Brunt TM (2016) How toxic is ibogaine? Clin Toxicol (Phila) 54:297–302. https://doi.org/10.3109/15563650.2016.1138226
Liu L, Wheeler SE, Venkataramanan R, Rymer JA, Pizon AF, Lynch MJ, Tamama K (2018) Newly emerging drugs of abuse and their detection methods: an ACLPS critical review. Am J Clin Pathol 149:105–116. https://doi.org/10.1093/ajcp/aqx138
Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276. https://doi.org/10.1111/bph.13222
Lowe RH, Abraham TT, Darwin WD, Herning R, Cadet JL, Huestis MA (2009) Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 105:24–32. https://doi.org/10.1016/j.drugalcdep.2009.05.027
Maas A, Madea B, Hess C (2018) Confirmation of recent heroin abuse: accepting the challenge. Drug Test Anal 10:54–71. https://doi.org/10.1002/dta.2244
MacDonald E, Arnesen TM, Brantsaeter AB, Gerlyng P, Grepp M, Hansen BA, Jonsrud K, Lundgren B, Mellegard H, Moller-Stray J, Ronning K, Vestrheim DF, Vold L (2013) Outbreak of wound botulism in people who inject drugs, Norway, October to November 2013. Euro Surveill 18:20630
Macher AM, Penders TM (2013) False-positive phencyclidine immunoassay results caused by 3,4-methylenedioxypyrovalerone (MDPV). Drug Test Anal 5:130–132. https://doi.org/10.1002/dta.1371
Martins SS, Sampson L, Cerda M, Galea S (2015) Worldwide prevalence and trends in unintentional drug overdose: a systematic review of the literature. Am J Public Health 105:e29–e49. https://doi.org/10.2105/AJPH.2015.302843
Matsumoto RR, Seminerio MJ, Turner RC, Robson MJ, Nguyen L, Miller DB, O’Callaghan JP (2014) Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Pharmacol Ther 144:28–40. https://doi.org/10.1016/j.pharmthera.2014.05.001
McDonald R, Strang J (2016) Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 111:1177–1187. https://doi.org/10.1111/add.13326
Mechoulam R (1970) Marihuana chemistry. Science 168:1159–1166
Mechoulam R (2000) Looking back at Cannabis research. Curr Pharm Des 6:1313–1322
Megarbane B, Chevillard L (2013) The large spectrum of pulmonary complications following illicit drug use: features and mechanisms. Chem Biol Interact 206:444–451. https://doi.org/10.1016/j.cbi.2013.10.011
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 10:153. https://doi.org/10.3389/fnins.2016.00153
Minami M, Satoh M (1995) Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res 23:121–145
Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ (2018) Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 32:411–420. https://doi.org/10.1007/s40263-018-0519-3
Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632. https://doi.org/10.1002/dta.1620
Mowry JB, Spyker DA, Brooks DE, Zimmerman A, Schauben JL (2016) 2015 annual report of the American Association of Poison Control Centers’ national poison data system (NPDS): 33rd annual report. Clin Toxicol (Phila) 54:924–1109. https://doi.org/10.1080/15563650.2016.1245421
Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M (2015) Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol 33:175–194. https://doi.org/10.1007/s11419-015-0270-0
National Academies of Sciences E and Medicine (2017) The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. The National Academies Press, Washington
National Institute on Drug Abuse (NIDA) (2018) Overdose death rates. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 15 Nov 2018
O’Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM (2017) Deaths involving fentanyl, fentanyl analogs, and U-47700 – 10 states, July-December 2016. MMWR Morb Mortal Wkly Rep 66:1197–1202. https://doi.org/10.15585/mmwr.mm6643e1
Odenwald M, al’Absi M (2017) Khat use and related addiction, mental health and physical disorders: the need to address a growing risk. East Mediterr Health J 23:236–244
Palamar JJ, Martins SS, Su MK, Ompad DC (2015) Self-reported use of novel psychoactive substances in a US nationally representative survey: prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug Alcohol Depend 156:112–119. https://doi.org/10.1016/j.drugalcdep.2015.08.028
Palmateer NE, Hope VD, Roy K, Marongiu A, White JM, Grant KA, Ramsay CN, Goldberg DJ, Ncube F (2013) Infections with spore-forming bacteria in persons who inject drugs, 2000-2009. Emerg Infect Dis 19:29–34. https://doi.org/10.3201/eid1901.120044
Patrick ME, O’Malley PM, Kloska DD, Schulenberg JE, Johnston LD, Miech RA, Bachman JG (2016) Novel psychoactive substance use by US adolescents: characteristics associated with use of synthetic cannabinoids and synthetic cathinones. Drug Alcohol Rev 35:586–590. https://doi.org/10.1111/dar.12372
Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI (2016) Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet 55:1059–1077. https://doi.org/10.1007/s40262-016-0383-6
Penninga EI, Graudal N, Ladekarl MB, Jurgens G (2016) Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication – a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 118:37–44. https://doi.org/10.1111/bcpt.12434
Peters FT, Martinez-Ramirez JA (2010) Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 32:532–539. https://doi.org/10.1097/FTD.0b013e3181f33411
Petrie M, Lynch KL, Ekins S, Chang JS, Goetz RJ, Wu AH, Krasowski MD (2013) Cross-reactivity studies and predictive modeling of “Bath salts” and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol (Phila) 51:83–91. https://doi.org/10.3109/15563650.2013.768344
Pettersson Bergstrand M, Helander A, Hansson T, Beck O (2017) Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal 9:640–645. https://doi.org/10.1002/dta.2003
Phillips KA, Hirsch GA, Epstein DH, Preston KL (2012) Cardiac complications of unwitting co-injection of quinine/quinidine with heroin in an intravenous drug user. J Gen Intern Med 27:1722–1725. https://doi.org/10.1007/s11606-012-2089-2
Pizon AF, Lynch MJ, Benedict NJ, Yanta JH, Frisch A, Menke NB, Swartzentruber GS, King AM, Abesamis MG, Kane-Gill SL (2018) Adjunct ketamine use in the management of severe ethanol withdrawal. Crit Care Med 46:e768–e771. https://doi.org/10.1097/CCM.0000000000003204
Presley CC, Lindsley CW (2018) DARK classics in chemical neuroscience: opium, a historical perspective. ACS Chem Neurosci 9:2503–2518. https://doi.org/10.1021/acschemneuro.8b00459
Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42. https://doi.org/10.1007/s13181-011-0193-z
Regester LE, Chmiel JD, Holler JM, Vorce SP, Levine B, Bosy TZ (2015) Determination of designer drug cross-reactivity on five commercial immunoassay screening kits. J Anal Toxicol 39:144–151. https://doi.org/10.1093/jat/bku133
Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo Gomez MM, Lange RA (2017) Beta-blockers, cocaine, and the unopposed alpha-stimulation phenomenon. J Cardiovasc Pharmacol Ther 22:239–249. https://doi.org/10.1177/1074248416681644
Roach JJ, Shenvi RA (2018) A review of salvinorin analogs and their kappa-opioid receptor activity. Bioorg Med Chem Lett 28:1436–1445. https://doi.org/10.1016/j.bmcl.2018.03.029
Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R (2014) Pharmacology of hallucinations: several mechanisms for one single symptom? Biomed Res Int 2014:307106. https://doi.org/10.1155/2014/307106
Ruiz-Colon K, Chavez-Arias C, Diaz-Alcala JE, Martinez MA (2014) Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int 240:1–8. https://doi.org/10.1016/j.forsciint.2014.03.015
Safer DJ (2016) Recent trends in stimulant usage. J Atten Disord 20:471–477. https://doi.org/10.1177/1087054715605915
Sanger DJ (2004) The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs 18(Suppl 1):9–15; discussion 41, 43–45. https://doi.org/10.2165/00023210-200418001-00004
Satzinger G, Hartenstein J, Herrmann M, Heldt W (1975) Cyclic amino acids. US4024175A
Scheidweiler KB, Huestis MA (2014) Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1327:105–117. https://doi.org/10.1016/j.chroma.2013.12.067
Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50:458–470. https://doi.org/10.3109/15563650.2012.702218
Sena SF, Kazimi S, Wu AH (2002) False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin Chem 48:676–677
Shang Y, Filizola M (2015) Opioid receptors: structural and mechanistic insights into pharmacology and signaling. Eur J Pharmacol 763:206–213. https://doi.org/10.1016/j.ejphar.2015.05.012
Shulman J, Pizon A, Lynch M (2017) Trends in gabapentin abuse reported to poison centers, 2012-2015 (abstract). Clin Toxicol (Phila) 55:689–868. https://doi.org/10.1080/15563650.2017.1348043
Sieghart W (2015) Allosteric modulation of GABAA receptors via multiple drug-binding sites. Adv Pharmacol 72:53–96. https://doi.org/10.1016/bs.apha.2014.10.002
Simpson D, Braithwaite RA, Jarvie DR, Stewart MJ, Walker S, Watson IW, Widdop B (1997) Screening for drugs of abuse (II): cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Ann Clin Biochem 34(Pt 5):460–510. https://doi.org/10.1177/000456329703400502
Sinner B, Graf BM (2008) Ketamine. Handb Exp Pharmacol 182:313–333. https://doi.org/10.1007/978-3-540-74806-9_15
Skaugen JM, Scoccimarro A, Pizon AF, Rymer JA, Giannoutsos S, Ekins S, Krasowski MD, Tamama K (2019) Novel ketamine analogs cause a false positive phencyclidine immunoassay. Ann Clin Biochem 56:598–607. https://doi.org/10.1177/0004563219858125
Smith JP, Sutcliffe OB, Banks CE (2015) An overview of recent developments in the analytical detection of new psychoactive substances (NPSs). Analyst 140:4932–4948. https://doi.org/10.1039/c5an00797f
Smith RV, Havens JR, Walsh SL (2016) Gabapentin misuse, abuse and diversion: a systematic review. Addiction 111:1160–1174. https://doi.org/10.1111/add.13324
Solimini R, Rotolo MC, Pellegrini M, Minutillo A, Pacifici R, Busardo FP, Zaami S (2017) Adulteration practices of psychoactive illicit drugs: an updated review. Curr Pharm Biotechnol 18:524–530. https://doi.org/10.2174/1389201018666170710184531
Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA (2017) Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol 13:71–87. https://doi.org/10.1007/s13181-016-0595-z
Spiller HA, Hays HL, Aleguas A Jr (2013) Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 27:531–543. https://doi.org/10.1007/s40263-013-0084-8
Stankowski RV, Kloner RA, Rezkalla SH (2015) Cardiovascular consequences of cocaine use. Trends Cardiovasc Med 25:517–526. https://doi.org/10.1016/j.tcm.2014.12.013
Stanley TH (1992) The history and development of the fentanyl series. J Pain Symptom Manag 7:S3–S7
Stanley TH, Egan TD, Van Aken H (2008) A tribute to Dr. Paul A. J. Janssen: entrepreneur extraordinaire, innovative scientist, and significant contributor to anesthesiology. Anesth Analg 106:451–462, table of contents. https://doi.org/10.1213/ane.0b013e3181605add
Sternbach LH (1979) The benzodiazepine story. J Med Chem 22:1–7
Straseski JA, Stolbach A, Clarke W (2010) Opiate-positive immunoassay screen in a pediatric patient. Clin Chem 56:1220–1223. https://doi.org/10.1373/clinchem.2009.137596
Substance Abuse and Mental Health Services Administration (SAMHSA) (2018) Key substance use and mental health indicators in the United States: results from the 2017 National Survey on Drug Use and Health. In: US Department of Health and Human Services (ed)
Sugiura T, Waku K (2002) Cannabinoid receptors and their endogenous ligands. J Biochem 132:7–12
Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, Poklis A (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56:129–139. https://doi.org/10.1016/j.psym.2014.11.002
Szmuszkovicz J (1976) Analgesic n-(2-aminocycloaliphatic)benzamides. US4098904A
Tahara T, Araki K, Shiroki M, Matsuo H, Munakata T (1978) Syntheses and structure-activity relationships of 6-aryl-4H-s-triazolo[3,4-c]thieno[2,3-e] [1,4]diazepines. Arzneimittelforschung 28:1153–1158
Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, Koyama F, Matsumoto K, Moriyama T, Yamamoto LT, Watanabe K, Murayama T, Horie S (2002) Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands. J Med Chem 45:1949–1956
United Nations Office for Drug Control and Crime Prevention (UNODCCP) (2001) Drug characterization and impurity profiling – background and concepts. United Nations Publication, New York
Van Lente F, Gatautis V (1998) Cost-efficient use of gas chromatography-mass spectrometry: a “piggyback” method for analysis of gabapentin. Clin Chem 44:2044–2045
van Wijk XMR, Yun C, Hooshfar S, Arens AM, Lung D, Wu AHB, Lynch KL (2018) A liquid-chromatography high-resolution mass spectrometry method for non-FDA approved benzodiazepines. J Anal Toxicol 43:316–320. https://doi.org/10.1093/jat/bky092
Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227. https://doi.org/10.1056/NEJMra1402309
Vuckovic S, Prostran M, Ivanovic M, Dosen-Micovic L, Todorovic Z, Nesic Z, Stojanovic R, Divac N, Mikovic Z (2009) Fentanyl analogs: structure-activity-relationship study. Curr Med Chem 16:2468–2474
Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A (2013) Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 346:f174. https://doi.org/10.1136/bmj.f174
Webster LR (2015) Opioid-induced constipation. Pain Med 16(Suppl 1):S16–S21. https://doi.org/10.1111/pme.12911
Weinstein AM, Rosca P, Fattore L, London ED (2017) Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psych 8:156. https://doi.org/10.3389/fpsyt.2017.00156
Weissman A, Milne GM, Melvin LS Jr (1982) Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516–523
Wermeling DP (2015) Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf 6:20–31. https://doi.org/10.1177/2042098614564776
Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF (2015) AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing delta9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther 354:328–339. https://doi.org/10.1124/jpet.115.225326
Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D (2012) The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med 13:26–34. https://doi.org/10.5811/westjem.2011.9.6866
Wong A, Little M, Caldicott D, Easton C, Andres D, Greene SL (2015) Analytically confirmed recreational use of Phenibut (beta-phenyl-gamma-aminobutyric acid) bought over the internet. Clin Toxicol (Phila) 53:783–784. https://doi.org/10.3109/15563650.2015.1059944
World Health Organization Department of Mental Health and Substance Abuse Management of Substance Abuse Team (NMH/MSD/MSB) Cannabis. https://www.who.int/substance_abuse/facts/cannabis/en/. Accessed 6 June 2019
Yogeeswari P, Ragavendran JV, Sriram D (2006) An update on GABA analogs for CNS drug discovery. Recent Pat CNS Drug Discov 1:113–118
Yuan J, Inami G, Mohle-Boetani J, Vugia DJ (2011) Recurrent wound botulism among injection drug users in California. Clin Infect Dis 52:862–866. https://doi.org/10.1093/cid/cir005
Zhu H, Wu LT (2016) Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med 10:429–436. https://doi.org/10.1097/ADM.0000000000000256
Zou S, Kumar U (2018) Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 19:833. https://doi.org/10.3390/ijms19030833
Acknowledgments
We are thankful to Jacqueline A. Rymer and Spiros Giannoutsos for their technical assistance in the laboratory.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tamama, K., Lynch, M.J. (2019). Newly Emerging Drugs of Abuse. In: Nader, M., Hurd, Y. (eds) Substance Use Disorders. Handbook of Experimental Pharmacology, vol 258. Springer, Cham. https://doi.org/10.1007/164_2019_260
Download citation
DOI: https://doi.org/10.1007/164_2019_260
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-33678-3
Online ISBN: 978-3-030-33679-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)